Omaha, NE Clinical Trials Report — July 2026

Omaha participants should act promptly if they match a study in prostate cancer, atopic dermatitis, endometrial cancer, or other conditions with trials scheduled to close within the next 90 days. Omaha has 23 recruiting trials approaching their enrollment deadlines, including 5 that accept healthy volunteers. Overall, 585 trials are recruiting across 220 local research facilities.

July brought 10 new trials, the same number reported in May. The new studies are concentrated in cancer, lung disease, thyroid disease, and atopic dermatitis, with industry sponsors responsible for 8 of the openings. People considering participation should contact study teams early because enrollment may end before a posted closing date if a trial reaches its target.

Closing windows in several major conditions

Prostate-related research has the largest number of closing-soon opportunities. Other studies involve dermatology, gynecologic cancer, blood cancer, autoimmune disease, and mental health.

• Prostate cancer (4 trials)
• Atopic dermatitis (2 trials)
• Endometrial cancer (2 trials)
• Prostatic neoplasms (2 trials)
• AML with mutated NPM1 (1 trial)
• Amnio-Maxx (1 trial)
• Advanced malignant neoplasm (1 trial)
• Autoimmune bullous dermatosis (1 trial)
• AML (1 trial)
• Bipolar I disorder (1 trial)

Healthy volunteers have 51 recruiting opportunities in Omaha overall, but only 1 of the 10 trials opened in July accepts healthy participants. Five of the closing-soon trials also accept healthy volunteers. Eligibility can depend on age, medications, medical history, and the ability to attend repeated visits, so prospective participants should verify requirements directly with each site.

Major Phase 2 and Phase 3 studies open locally

Several July openings are late-stage drug studies sponsored by AstraZeneca, Bristol-Myers Squibb, and Nektar Therapeutics. These trials cover serious cancers and moderate-to-severe atopic dermatitis, while a Phase 2 study is evaluating an investigational treatment for Graves’ disease.

• NCT07720284 is AstraZeneca’s Phase 3 study of dato-DXd plus rilvegostomig versus standard care for adults with high-risk muscle-invasive urothelial carcinoma after surgery. The study plans to enroll 915 participants and evaluates adjuvant treatment for people with residual high-risk disease.
• NCT07680790, sponsored by Bristol-Myers Squibb, is the Phase 3 IZABRIGHT-Lung02 study for previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. It compares izalontamab brengitecan plus osimertinib with osimertinib alone or osimertinib plus platinum-based chemotherapy in 850 participants.
• NCT07690371 is Nektar Therapeutics’ Phase 3 study of rezpegaldesleukin for people at least 12 years old with moderate-to-severe atopic dermatitis. The randomized, double-blind study plans to enroll 510 participants and compares treatment with placebo.
• NCT07682896 is a Phase 2 Yarrow Bioscience study of YB-101 in Graves’ disease. The trial plans to enroll 232 participants and will assess thyroid effects, safety, tolerability, and how the drug is distributed in the body.
• NCT07680764 is a Bristol-Myers Squibb Phase 2 study for locally advanced or metastatic non-small cell lung cancer. It evaluates imzokitug with pumitamig and platinum-doublet chemotherapy versus pumitamig with chemotherapy, with planned enrollment of 160 participants.

The full set of new openings includes 6 drug trials, 2 biological studies, 1 behavioral study, and 1 device study. Conditions represented include bladder and kidney cancers, COPD, Graves’ disease, non-muscle-invasive bladder cancer, lung cancer, and atopic dermatitis. AstraZeneca and Bristol-Myers Squibb each sponsor 2 new trials; Nektar Therapeutics, PeptiDream, Quality Living, the University of Nebraska, UroGen Pharma, and Yarrow Bioscience each sponsor one.

University of Nebraska Medical Center is the main access point

The University of Nebraska Medical Center is Omaha’s dominant clinical research hub, with 215 recruiting trials. The city’s other high-volume locations include Nebraska Medicine-Village Pointe and Nebraska Cancer Specialists, each with 41 trials, followed closely by Alegent Health Bergan Mercy Medical Center with 40.

• University of Nebraska Medical Center (215 trials)
• Nebraska Medicine-Village Pointe (41 trials)
• Nebraska Cancer Specialists (41 trials)
• Alegent Health Bergan Mercy Medical Center (40 trials)
• Alegent Health Lakeside Hospital (37 trials)
• Alegent Health Immanuel Medical Center (37 trials)
• Nebraska Methodist Hospital (32 trials)
• Children’s Hospital and Medical Center of Omaha (28 trials)
• Research Site (26 trials)
• Nebraska Cancer Specialists/Oncology Hematology West PC - MECC (19 trials)
• Creighton University Medical Center (19 trials)
• Oncology Associates PC (15 trials)

People seeking cancer studies will find particularly dense options at UNMC, Nebraska Cancer Specialists, the Alegent Health hospitals, Nebraska Methodist Hospital, and oncology-focused practices. Children’s Hospital and Medical Center of Omaha provides a local option for pediatric research, although only 1 of July’s new trials includes children.

Who may qualify and where else to search

All 10 new trials include older adults. None is limited exclusively to women or men. Most new studies are industry-sponsored, while two are classified as other sponsorship types. Healthy volunteers remain an active recruitment group in Omaha, but the limited number of newly opened healthy-volunteer studies makes early screening especially useful.

Participants willing to travel can also look in Grand Island and Lincoln, which each have 2 recruiting trials. These nearby Nebraska options may be useful when an Omaha study has closed enrollment or when eligibility requirements differ between sites.

Omaha’s recent monthly totals were 11 new trials in February, 12 in March, 11 in April, 7 in May, 10 in June, and 10 in July. With late-stage cancer and dermatology studies now opening alongside a substantial active research base, local patients and volunteers should monitor listings and contact UNMC or nearby specialty sites as August enrollment opportunities develop.